Control of type 2 diabetes mellitus: problems and prospects for their solution

Código QR

Control of type 2 diabetes mellitus: problems and prospects for their solution

Important medico-social and economic implications of type 2 diabetes mellitus (DM2) are determined by its continuously growing prevalence, frequencyand severity of complications related to inadequate glycemic control. Large-scale studies (UKPDS, VADT, ACCORD, ADVANCE) havedemonstrated controversial...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tatiana Ivanovna Romantsova, Irina Vladimirovna Glinkina
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2009
Materias:	type 2 diabetes mellitus postprandial glycemia dpp-iv inhibitors Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/ebc3e71c7bb745a0bb455a04eded1eed
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Causes behind the failure to manage patients with type 2 diabetes mellitus. The role of postprandial glycemia
por: Elena Valer'evna Doskina
Publicado: (2010)

Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
por: Marina Vladimirovna Shestakova
Publicado: (2010)

Is the 1,5-anhydro-D-glucitol test a promising tool for monitoring compensation and treatment of diabetes mellitus?
por: Margarita Ivanovna Arbuzova, et al.
Publicado: (2010)

Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors
por: Alexander Sergeevich Ametov, et al.
Publicado: (2010)

Actual ambulatory care in patients with type 2 diabetes mellitus in Russian Federation according to open label prospectiveobservational study DIA-CONTROL
por: Marina Vladimirovna Shestakova
Publicado: (2011)

Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus
por: Editorial team Diabetes Mellitus
Publicado: (2012)

New prospects in the treatment of diabetes mellitus
por: Minara Shamkhalovna Shamkhalova, et al.
Publicado: (2012)

Systems of continuous subcutaneous insulin infusion to maintain metabolic compensation for type 1 diabetes mellitus among children and adolescents
por: Elena B. Bashnina, et al.
Publicado: (2019)

Rannyaya kombinirovannaya terapiya pri sakharnom diabete 2 tipa
por: Alexander Sergeevich Ametov, et al.
Publicado: (2011)

Vildagliptin and its role in the treatment of diabetes mellitus
por: Yury Shavkatovich Khalimov
Publicado: (2010)

Modern antihyperglycemic agents prescribed in Russia for type 2 diabetes mellitus
por: Yury Ivanovich Suntsov
Publicado: (2012)

Heart failure in diabetes: effects of anti-hyperglycemic drug therapy
por: Gagik R. Galstyan, et al.
Publicado: (2016)

Peculiarities of night EEG-monitoring of sleep in children with type 1 diabetes mellitus depending on the glycemia level
por: Alexandra N. Demyanenko, et al.
Publicado: (2018)

Resolution on the results of the first working meeting of the scientific advisory board «Actual problems of glycemic variability as a new criterion of glycemic control and safety of diabetes therapy»
por: Mikhail B. Antsiferov, et al.
Publicado: (2019)

Topical problems of diabetes treatment during pregnancy
por: Irina Yur'evna Demidova, et al.
Publicado: (2009)

Current state-of-the-art in the safe and efficient management of type 2 diabetes mellitusKey words: diabetes mellitus, vascular complications, glycemia control, management of diabetes mellitus
por: Alexander Sergeevich Ametov, et al.
Publicado: (2009)

Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications
por: Elena Valer'evna Biryukova
Publicado: (2014)

First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients
por: Karina Oganesovna Galstyan, et al.
Publicado: (2016)

Effectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean population
por: Anna A. Mosikian, et al.
Publicado: (2018)

Urinary excretion of type IV collagen as an early marker of renal fibrosis in patients with diabetes mellitus
por: Irina Arkad'evna Bondar', et al.
Publicado: (2011)

Expert committee on introduction of incretin-based therapy in Russia: advance and failure
por: Editorial team Diabetes Mellitus
Publicado: (2012)

Type 2 diabetes mellitus in elderly patients treated with endocrinologists in clinical practice
por: Elena V. Biryukova
Publicado: (2019)

The role of phenofibrate in the treatment of microvascular complications of type 2 diabetes mellitus
por: Larisa Viktorovna Koshel', et al.
Publicado: (2009)

Effects of metformin on body weight in patients with type 2 diabetes mellitus,receiving insulin analogue treatment
por: Tatiana Ivanovna Romantsova, et al.
Publicado: (2013)

Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents
por: Stefan D. Anker
Publicado: (2019)

Main results of the ADVANCE study: clinical interpretation for endocrinologists
por: Alsu Gafurovna Zalevskya, et al.
Publicado: (2009)

Russian Association of Endocrinologists reports commencement of Trajenta clinical use
por: Editorial team Diabetes Mellitus
Publicado: (2012)

Metformin regulates glycemic homeostasis in patients with type 2 diabetes mellitus as an NO donor
por: Ivan Sergeevich Kuznetsov, et al.
Publicado: (2013)

Relevance of results of the ADVANCE study for diabetes control in Russia
por: Ivan Ivanovich Dedov, et al.
Publicado: (2009)

Intensification of glucose-lowering treatment in patients with diabetes mellitus type 2 on insulin therapy: Perspectives of dapagliflozin
por: Olga Yuryevna Sukhareva, et al.
Publicado: (2016)

Insulin resistance in pathogenesis of type 2 diabetes mellitus
por: Alexander Yur'evich Mayorov
Publicado: (2011)

Role of incretin based therapies in the treatment of diabetic kidney disease
por: Paola Fioretto, et al.
Publicado: (2018)

Heart failure in diabetes: From an increased risk to a treatment target
por: Eberhard Standl
Publicado: (2018)

Diabetes mellitus type 2: a new indication for hypercortisolism screening?
por: Natalya Ivanovna Volkova, et al.
Publicado: (2012)

Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia
por: Lyudmila Viktorovna Nedosugova, et al.
Publicado: (2014)

Vildagliptin: the first innovative DDP-4 inhibitor
por: Edvin Villkhauer
Publicado: (2010)

Metformin regulates glycemic homeostasis in patients with type 2 diabetes mellitus as an NO donor
por: Ivan Sergeevich Kuznetsov, et al.
Publicado: (2013)

Optimization of therapy of type 2 diabetes mellitus with the oral hypoglycemic agent glimepiride
por: Tatiana Ivanovna Romantsova, et al.
Publicado: (2010)

Urate-lowering effects of dipeptidyl peptidase-4 inhibitors
por: Taras S. Panevin, et al.
Publicado: (2020)

The new drug saxagliptin is now registrated in Russia
por: Editorial team Diabetes Mellitus
Publicado: (2010)